广州市高层次人才（优秀专家）、珠江学者特聘教授、人社部高层留学人才（2019），医学免疫学专业。广州医科大学南山优秀人才，呼吸疾病国家重点实验室PI，教授，博导。
一直从事急性感染与病毒免疫研究，并在澳大利亚墨尔本大学诺贝尔奖得主Peter Doherty实验室学习和工作6年，在T细胞抗新发传染病病毒感染相关研究领域取得国际领先成果。先后阐述了H7N9引起的细胞因子风暴（PNAS 2014），H7N9感染康复需要多种细胞免疫机制共同作用（Nature communications 2015），及H7N9急性感染可能会引起部分T细胞衰竭（Nature communications 2018）。新冠爆发后，积极参与了新冠感染免疫研究，发现了在一定的中和抗体水平下，T细胞免疫对重症COVID-19病人康复至关重要（Am J Respir Crit Care Med 2020）。 随后，发现了核酸和抗体均为阴性的密切接触者体内产生新冠病毒特异性T细胞反应，阐述了新冠暴露会产生连续感染谱，提示人们对“病毒感染”需要重新定义，以便更好评价的疫苗免疫后群体免疫力（Nature communications 2021）。在两针灭活疫苗的基础上，开展了第三针异源加强针免疫（亚单位疫苗、mRNA疫苗、腺病毒吸入或腺病毒肌注），验证了第三针亚单位疫苗加强相比同源加强显著提高了针对SARS-CoV-2中和抗体产生，该中和抗体对多种变异株如Omicron都有很好的交叉反应性（Emerging Microbes & Infections 2022）。在关注新冠病毒感染引起的中和抗体和病毒特异性T细胞反应外，我们也研究了结合抗体的抗体依赖的细胞杀伤作用（Antibody-dependent cellular cytotoxicity ，ADCC)保护作用。
共发表SCI论文39篇，以第一作者或通讯作者SCI论文18篇。
先后主持国家重点研发计划项目子课题1项、国家自然科学基金面上项目2项、广东省科技厅重点项目等多项课题。
Guangzhou high-level talents (outstanding experts), Zhujiang scholars' special professor, senior overseas study talent of the Ministry of Human Resources and Social Security (2019), majoring in medical immunology. Outstanding talent in Nanshan, Guangzhou Medical University, PI, professor and doctoral supervisor of the National Key Laboratory of Respiratory Diseases.
He has been engaged in research on acute infection and viral immunity, and has studied and worked in the laboratory of Peter Doherty, Nobel Prize winner of the University of Melbourne, Australia for 6 years, and has achieved international leading results in the field of research on T cell anti-new infectious diseases and viral infection. The cytokine storm caused by H7N9 (PNAS 2014), the recovery of H7N9 infection requires the joint action of multiple cellular immune mechanisms (Nature communications 2015), and the acute infection of H7N9 may cause some T cell failure (Nature communications 2018). After the outbreak of the new crown, we actively participated in the study of immunity for the new crown infection and found that T cell immunity is crucial to the recovery of severe COVID-19 patients at certain neutralizing antibodies (Am J Respir Crit Care Med 2020). Subsequently, close contacts with both nucleic acid and antibodies were found to produce a T-cell response in the new coronavirus in the body, explaining that the exposure to the new coronavirus will produce a continuous infection spectrum, suggesting that people need to redefine "viral infection" in order to better evaluate the herd immunity after vaccine immunity (Nature communications 2021). Based on the two inactivated vaccines, a third dose of heterologous enhancement injection was carried out (subunit vaccine, mRNA vaccine, adenovirus inhalation or adenovirus intramuscular injection), which verified that the third dose of subunit vaccine has significantly improved the production of SARS-CoV-2 neutralizing antibodies compared with homologous enhancement. This neutralizing antibody has good cross-reactivity to various variant strains such as Omicron (Emerging Microbes & Infections 2022). In addition to focusing on neutralizing antibodies and virus-specific T cell responses caused by COVID-19 infection, we also studied the antibody-dependent cellular cytotoxicity (ADCC) protection effect of antibodies binding.
A total of 39 SCI papers have been published, and 18 SCI papers have been published as the first author or corresponding author.
He has successively presided over a number of projects such as 1 sub-project of the National Key R&D Program, 2 projects of the National Natural Science Foundation, and key projects of the Guangdong Provincial Department of Science and Technology.
